Every year about 85,0000 new Cancer cases are diagnosed in India resulting in about 58,0000 Cancer related deaths every year. More than 60% of these affected patients are in the prime of their life between the ages of 35 and 65 years. With increasing life expectancy and changing life styles concomitant with development, the number of Cancer cases will be almost three times the current number (National Cancer Programme).
Present standard options of Cancer treatment namely Surgery, Chemotherapy and Radiotherapy result in partial cure with lot of side effects, deterioration of quality of life which further compounds the emotional and psychological distress associated with Cancer patients. So, how can SPMF®Therapy help Cancer patients?
How does SPMF®Therapy help?
Cancer treatment trials were conducted at the Institute of Aerospace Medicine, Indian Air Force, Bangalore, from July 2004 to July 2006 under the supervision of Wg Cdr (Dr) VG Vasishta (Retd). In this trial, all the patients had completed standard treatment modalities such as chemotherapy, surgery and radiotherapy; they were on palliative care and had volunteered for the Cancer treatment. All the patients were exposed to SPMF®Therapy, daily for 1 hour for 28 consecutive days and were assessed using the Karnofsky (Quality of life) Performance Scale scores before and after the exposure.
The statistical analysis of the results revealed a highly significant correlation between SPMF®Therapy exposure and reduction in the size of tumor, Karnofsky (Quality of life) score improvement and also survival period. 60% of the patients, who were given a few weeks to a few months of survival by their oncologists, survived for longer periods and even resumed their routine work.
45% of the patients who were on analgesics like morphine got Cancer pain relief to the extent that they were able to discontinue the medication after completion of Cancer treatment. The patients consistently showed significant reduction in tumour size and improvement in the Karnofsky (Quality of life) performance score after exposure to SPMF®Therapy. The promising and exciting results that have been received from thisTherapy have brought recognition for this technology not only from the national press and scientific community, but also from the international medical and academic communities.
Before starting SPMF®Therapy for Cancer treatment, routine hematological tests and proton density planning film (MRI) of affected area is done, depending on which the SPMF dose is calculated by a specially designed software. The treatment is for 1 hour every day for 28 consecutive days.
Sequentially Programmed Magnetic Field (SPMF®)Therapy
SPMF is a technology that delivers highly complex Sequentially Programmed Magnetic Fields, with precise command and control through a machine called a ‘AKTIS SOMA®. The fields can be precisely controlled and aligned onto the cancerous tissues by specially designed Magnetic Frequency Generators (MFG). SPMF acts by bringing the cell membrane potential from its negativity to its normal potential, the cell reaches a resting state after which it stops dividing, thus causing programmed cell death (Apoptosis) of the tumour tissue and shrinkage of the tumour after a certain period of time.
Based on the trial results and experiences of SPMF®Therapy, an improved form of the SPMF machine called AKTIS SOMA® has been developed which will be used for providing palliative care for Cancer patients at our center.
Hypothesized Mechanism in Tissue degeneration
It is known that normal resting cell membrane potential (Trans membrane potential, TMP) is -70mV to -90mV. It decreases to -40 to -60mV when infected and -15 to -30mV in Cancerous cells. Exposure to SPMF®Therapy, 1 hr everyday for 28 consecutive days normalizes the cell membrane potential to its resting state, thereby preventing mitosis of the Cancer cells and initiates apoptosis (programmed cell death).
SPMF increases the impedance of mitochondrial membrane, thereby cutting down the production of ATP and preventing mitosis. The normal cells are not influenced by the SPMF exposure as the SPMF Magnetic Frequency Generators (MFG’s) are aimed at the core of the tumour where the fields meet, furthermore, the signals are modulated depending on the proton density of the tumour tissue and impedance of their (normal cells) mitochondrial sensors.
SPMF exposure also prevents angiogenesis, which cuts down the nutrition supply to the tumour tissue.